Aptahem AB (publ) (NGM:APTA)
0.7140
+0.0440 (6.57%)
At close: May 20, 2026
Aptahem AB Earnings Call Transcripts
Fiscal Year 2025
-
A lead RNA aptamer for sepsis is advancing toward phase 2, with strong preclinical and phase 1 data. U.S. listing preparations are underway to access better valuation and regulatory incentives, while partnerships and expanded IP are being pursued for broader impact.